Celiac disease. New therapeutic alternatives based on a better knowledge of molecular pathogenesis;Enfermedad celíaca. Nuevas perspectivas terapéuticas basadas en un mejor conocimiento de su patogenia molecular

Acta Gastroenterologica Latinoamericana

Volumn 35, Issue 3, 2005, Pages 183-189

  Chirdo, Fernando G ^a   Garrote, José A ^b   Arranz, Eduardo ^b,c  

^a FACULTAD DE CIENCIAS EXACTAS   (Argentina)

^b UNIVERSITY OF VALLADOLID   (Spain)

^c UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Enfermedad cel aca; Inmunomodulaci n; Patogenia; Terapia

Indexed keywords

CELIAC DISEASE; GENETICS; HUMAN; IMMUNOLOGY; REVIEW;

CELIAC DISEASE; HUMANS;

EID: 27544468770     PISSN: 03009033     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Lundin KE, Scott H, Hansen T, et al. Gliadin-specific, HLA-DQ (α1*0501, β1*0201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients. J Exp Med 1993;178:187-196.
2. Nilsen EM, Lundin KE, Krajci P, et al. Gluten specific, HLA-DQ restricted T cells from celiac mucosa produce cytokines with Th1 or Th0 profile dominated by interferon gamma. Gut 1995;37:766-776.
3. Sollid LM. Coeliac disease: dissecting a complex inflammatory disorder. Nature Rev 2002;2:647-655.
4. Schuppan D, Hahn EG. Gluten and the gut - lessons for immune regulation. Science 2002; 297:2218-2220.
5. Arentz-Hansen H, Korner R, Molberg O, et al. The intestinal T cell response to a-gliadin in adult celiac disease is focused on a single deaminated glutamine targeted by tissue transglutaminase. J Exp Med 2000;191:603-612.
6. Anderson RP, Degano P, Godkin AJ, et al. In vivo antigen challenge in celiac disease identifies a single transglutaminase-modified peptide as a dominant A-gliadin T-cell epitope. Nat Med 2000;6:337-342.
7. Qiao SW, Bergseng E, Molberg O, et al. Antigen presentation to celiac lesion-derived T cells of a 33-mer gliadin peptide naturally formed by gastrointestinal digestion. J Immunol 2004;173:1757-1762.
8. Maiuri L, Ciacci C, Ricciardelli I, et al. Association between innate response to gliadin and activation of pathogenic T cells in coeliac disease. Lancet 2003;362:30-37.
9. Hue S, Mention JJ, Monteiro RC, et al. A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 2004;21:367-377.
10. Louka AS, Sollid LM. HLA in coeliac disease: unravelling the complex genetics of a complex disorder. Tissue Antigens 2003;61:105-117.
11. Karell K, Louka AS, Moodie SJ, et al. HLA types in celiac disease patients not carrying the DQA1*05-DQB1*02 (DQ2) heterodimer: results from the European Genetics Cluster on Celiac Disease. Hum Immunol 2003;64:469-477.
12. Polvi A, Arranz E, Fernández-Arquero M, et al. HLADQ2-negative celiac disease in Finland and Spain. Hum Immunol 1998;59:169-175.
13. Greco L, Corazza G, Babron MC, et al. Genome search in celiac disease. Am J Hum Genet 1998;62:669-675.
14. Ciclitira PJ, Ellis HJ. In vivo gluten ingestion in celiac disease. Dig Dis Sci 1998;16:337-340.
15. Ellis HJ, Pollock EC, Engel W, et al. Investigation of the putative immunodominant T cell epitopes in celiac disease. Gut 2003;52:212-217.
16. Fraser JS, Engel W, Ellis HJ, et al. Coeliac disease: in vivo toxicity of the putative immunodominant epitope. Gut 2003;52:1698-1702.
17. Arentz-Hansen H, McAdam SN, Molberg O, et al. Celiac lesion T cells recognize epitopes that cluster in regions of gliadins rich in proline residues. Gastroenterology 2002;123:803-809.
18. Shan L, Molberg O, Parrot I, et al. Structural basis for gluten intolerance in celiac sprue. Science 2002; 297:2275-2279.
19. Koning F. The molecular basis of celiac disease. J Mol Recognit 2003;16:333-336
20. Molberg O, Uhlen AK, Jensen T, et al. Mapping of gluten T cell epitopes in the bread wheat ancestors; implications for celiac disease. Gastroenterology 2005;128:393-401.
21. Vader LW, Stepniak DT, Bunnik EM, et al. Characterization of cereal toxicity for celiac disease patients based on protein homology in grains. Gastroenterology 2003; 125:1105-1113.
22. Molberg O, McAdam SN, Korner R, et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 1998; 4:713-17.
23. van de Wal Y, Kooy Y, Van Veelen P, et al. Selective deamination by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. J Immunol 1998;161:1585-1588.
24. Vader W, Kooy Y, Van Veelen P, et al. The gluten response in children with celiac disease is directed toward multiple gliadin and glutenin peptides. Gastroenterology 2002;122:1729-1737.
25. Kim CY, Quarsten H, Bergseng E, et al. Structural basis for HLA-DQ2-mediated presentation of gluten epitopes in celiac disease. Proc Nat Acad Sci 2004;101:4175-4179.
26. Costantini S, Rossi M, Colonna G and Facchiano AM. Modelling of HLA-DQ2 and its interaction with gluten peptides to explain molecular recognition in celiac disease. J Mol Graph Model 2005;23:419-431.
27. Nilsen EM, Jahnsen FL, Lundin KE, et al. Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with celiac disease. Gastroenterology 1998;115:551-563.
28. Troncone R, Gianfrani C, Mazzarela G, et al. The majority of gliadin-specific T cell clones from the coeliac small intestinal mucosa produce both γ-interferon and IL-4. Dig Dis Sci 1998;43:156-161
29. Forsberg G, Hernell O, Melgar S, et al. Paradoxical coexpression of proinflammatory and down-regulatory cytokines in intestinal T cells in childhood celiac disease. Gastroenterology 2002;123:667-678.
30. Monteleone G, Pender SLF, Alstead E, et al. Role of interferon-α in promoting T helper cell type 1 responses in the small intestine in coeliac disease. Gut 2001;48:425-429.
31. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players of T cell responses. Immunity 2003;19:641-644.
32. Salvati VM, MacDonald TT, Bajaj-Elliot M, et al. Interleukin 18 and associated markers of T helper cell type 1 activity in celiac disease. Gut 2002;50:186-190.
33. Maiuri L, Ciacci C, Auricchio S, et al. Interleukin-15 mediates epithelial changes in celiac disease. Gastroenterology 2000;119:996-1006.
34. Salvati VM, Mazzarella G, Gianfrani C, et al. Recombinant human interleukin 10 suppresses gliadin dependent T cell activation in ex vivo cultured coeliac intestinal mucosa. Gut 2005;54:46-53.
35. Beckett CG, Dell'Olio D, Kontakou M, et al. Analysis of interleukin -4 and interleukin-10 and their association with the lymphatic infiltrate in the small intestine of patients with coeliac disease. Gut 1996;39:818-823.
36. Lionetti P, Pazzaglia A, Moriondo M, et al. Differing patterns of TGF-ß expression in normal intestinal mucosa and in active celiac disease. J Pediatr Gastroenterol Nutr 1999;29:308-313.
37. Chirdo FG., Millington OR, Beacock-Sharp H, McI Mowat A. Immunomodulatory Dendritic cells in intestinal lamina propria. Eur. J Immunol 2005;35:1831-1840.
38. Daum S, Bauer U, Foss HD, et al. Increased expression of mRNA for matrix metalloproteinase-1 and -3 and tissue inhibitor of metalloproteinase-1 in intestinal biopsy specimens from patients with coeliac disease. Gut 1999;44:17-25.
39. Ciccocioppo R, Di Sabatino A, Bauer M, et al. Matrix metalloproteinase pattern in celiac duodenal mucosa. Lab Invest 2005;85:397-407.
40. Hill ID, et al. Guideline for the diagnosis and treatment of celiac disease in children. J Pediatr Gastroenterol Nutr 2005;40:1-19.
41. Pietzak MM. Follow-up of patients with celiac disease: achieving compliance with treatment. Gastroenterology 2005;128: S135-S141.
42. Case S. The gluten-free diet: how to ptovide effective education and resources. Gastroenterology 2005;128:S128-S134.
43. Sollid LM and Khosla C. Future therapeutic options for coeliac disease. Nat Clin Pract 2005;2:140-147.
44. Hausch F, Shan L, Santiago NA, et al. Intestinal digestive resistance of immunodominant gliadin peptides. Am J Physiol Gastrointest Liver Phisiol 2002;283:G996-G1003.
45. Marti T, Molberg O, Li Q, et al. Prolyl endopeptidase-mediated destruction of T cell epitopes in whole gluten: chemical and immunological characterization. J Pharmacol Exp Ther 2005;312:19-26.
46. Molberg O, McAdam SN, Lundin KE, et al. T cells from celiac disease lesions recognize gliadin epitopes deaminated in situ by endogenous tissue transglutaminase. Eur J Immunol 2001;31:1317-1323.
47. Sette A, O'Sullivan D, Krieger JI, et al. MHC-antigen-T cell interactions: an overview. Semin Immunol 1991;3:195-2002.
48. Appel H, Seth NP, Gauthier L, Wucherpfenning KW. Anergy induction by dimeric TCR ligands. J Immunol 2001;166:5279-85.
49. Mowat A. McI. Anatomical basis of tolerance and immunity to intestinal antigens. Nature Rev Immunol 2003;3:331-341.
50. Senger S, Luongo D, Maurano F, et al. Intranasal administration of a recombinant alpha-gliadin down-regulates the immune response to wheat gliadin in DQ8 transgenic mice. Immunol Lett 2003;88:127-134.
51. Sandborn WJ and Targan SR. Biologic therapy of inflammatory bowel disease. Gastroenterology 2002;122:1592-1608.
52. Mention JJ, Ben Ahmed M, Begue B, et al. Interleukin 15: a key to disrupted intraepithelial lymphocyte homeostasis and lymphomagenesis in celiac disease. Gastroenterology 2003;125:730-45.
53. Cheroutre H, Madakamutil L. Acquired and natural memory T cells join forces at the mucosal front line. Nat Rev Immunol 2004;4:290-300.
54. Giovannini C, Matarrese P, Scazzocchio B, et al. Wheat gliadin induces apoptosis of intestinal cells via an autocrine mechanism involving Fas-Fas ligand pathway. FEBS Lett 2003;540:117-124
55. Londei M, Ciacci C, Ricciardelli I, et al. Gliadin as a stimulator of innate responses in celiac disease. Mol Immunol 2005;42:913-8.
56. Meresse B, Chen Z, Ciszewski C, et al. Coordinated induction by IL15 of a TCR-independent NKG2D signalling pathway converts CTL into Lymphokine-activated killer cells in celiac disease. Immunity 2004;21:357-66.